
Injections outperform inhaled measles vaccine
Injected measles vaccine stimulates a significantly stronger immune response than inhaled vaccine, a new study reports.
In a trial funded by the Bill and Melinda Gates Foundation, researchers randomly assigned 2004 Indian children aged 9 to 12 months who were eligible for a first dose of measles
Although 1956 (97.6%) of all the children were followed to day 91, thawed specimens precluded evaluating outcome data for 331 children. In the per-protocol population, researchers were able to evaluate data on 1560 (77.8%) of 2004 children. At day 91 in this population, 662 of 775 children (85.4%) who received the aerosol vaccine were seropositive for antibodies compared with 743 of 785 children (94.6%) who received injections. The full-analysis data set yielded similar results: 85.4% seropositivity among children who received inhaled vaccine and 94.7% among recipients of injected vaccine.
The study helps clarify the immunogeneticy of aerosolized measles vaccine, for which data have been inconsistent. The researchers conclude that the inhaled vaccine is immunogenic but falls short of injected vaccine in rates of antibody seropositivity.
Moreover, although the inhaled vaccine has the advantage of being needle free, it can’t deliver multiple vaccines in 1 dose as can the injected
The
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.














